ReviewAJR. American journal of roentgenology2018
Imaging Prostate Cancer With Prostate-Specific Membrane Antigen PET/CT and PET/MRI: Current and Future Applications.
Review in AJR. American journal of roentgenology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Meta-analysis ofCancer imaging : the official publication of the International Cancer Imaging Society · 2023Pooled it
- Dynamic 18 F-PSMA-1007 PET-CT kinetics as a prognostic marker in newly diagnosed prostate cancer: a prospective pilot study.World journal of urology · 2026Article
- Role of PSMA PET/CT in imaging and management of prostate cancer.Current opinion in oncology · 2025Review
- Brain imaging and machine learning reveal uncoupled functional network for contextual threat memory in long sepsis.Scientific reports · 2024Article
- Review
- PSMA PET imaging in the diagnosis and management of prostate cancer.Abdominal radiology (New York) · 2023Review
- PSMA Expression Correlates with Improved Overall Survival and VEGF Expression in Glioblastoma.Biomedicines · 2023Article
- Necessity of Pelvic Lymph Node Irradiation in Patients with Recurrent Prostate Cancer after Radical Prostatectomy in the PSMA PET/CT Era: A Narrative Review.Biomedicines · 2022Review
- Automated radiosynthesis of [Journal of labelled compounds & radiopharmaceuticals · 2021Article
- Prospective Evaluation ofAJR. American journal of roentgenology · 2020Article
- Modular Medical Imaging Agents Based on Azide-Alkyne Huisgen Cycloadditions: Synthesis and Pre-Clinical Evaluation ofChemistry (Weinheim an der Bergstrasse, Germany) · 2020Article
- Local staging of prostate cancer with imaging: can hybrid imaging be the solution?Translational andrology and urology · 2020Article
- Current Status of PSMA-Radiotracers for Prostate Cancer: Data Analysis of Prospective Trials Listed on ClinicalTrials.gov.Pharmaceuticals (Basel, Switzerland) · 2020Article
- Accuracy ofAmerican journal of nuclear medicine and molecular imaging · 2020Article
- Management algorithms for prostate-specific antigen progression in prostate cancer: Biochemical recurrence after definitive therapy and progression to non-metastatic castrate-resistant prostate cancer.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2019Review
- Comparison of PSMA-ligand PET/CT and multiparametric MRI for the detection of recurrent prostate cancer in the pelvis.European journal of nuclear medicine and molecular imaging · 2019Article
- Novel Structured Reporting Systems for Theranostic Radiotracers.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2019Review
- A Festschrift in Honor of Edward M. Messing, MD, FACS.Bladder cancer (Amsterdam, Netherlands) · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 4 countries.
Funding
Abstract
objectiveThe purpose of this article is to describe the large number of radiotracers being evaluated for prostate-specific membrane antigen (PSMA) PET, which is becoming a central tool in the staging of prostate cancer.
conclusionPSMA PET is a highly promising modality for the staging of prostate cancer because of its higher detection rate compared with that of conventional imaging. Both PET/CT and PET/MRI offer benefits with PSMA radiotracers, and PSMA PET findings frequently lead to changes in management. It is imperative that subsequent treatment changes be evaluated to show improved outcomes. PSMA PET also has potential applications, including patient selection for PSMA-based radioligand therapy and evaluation of treatment response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.